Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment - PubMed (original) (raw)

Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment

M Million et al. Nutr Diabetes. 2013.

Abstract

Background: Antibiotics, used for 60 years to promote weight gain in animals, have been linked to obesity in adults and in children when administered during early infancy. Lactobacillus reuteri has been linked to obesity and weight gain in children affected with Kwashiorkor using ready-to-use therapeutic food. In contrast, Escherichia coli has been linked with the absence of obesity. Both of these bacteria are resistant to vancomycin.

Objectives and methods: We assessed vancomycin-associated weight and gut microbiota changes, and tested whether bacterial species previously linked with body mass index (BMI) predict weight gain at 1 year. All endocarditis patients treated with vancomycin or amoxicillin in our center were included from January 2008 to December 2010. Bacteroidetes, Firmicutes, Lactobacillus and Methanobrevibacter smithii were quantified using real-time PCR on samples obtained during the 4-6 weeks antibiotic regimen. L. reuteri, L. plantarum, L. rhamnosus, Bifidobacterium animalis and E. coli were quantified on stool samples obtained during the first week of antibiotics.

Results: Of the193 patients included in the study, 102 were treated with vancomycin and 91 with amoxicillin. Vancomycin was associated with a 10% BMI increase (odds ratio (OR) 14.1; 95% confidence interval (CI; 1.03-194); P=0.047) and acquired obesity (4/41 versus 0/56, P=0.01). In patients treated with vancomycin, Firmicutes, Bacteroidetes and Lactobacillus increased, whereas M. smithii decreased (P<0.05). The absence of E. coli was an independent predictor of weight gain (OR=10.7; 95% CI (1.4-82.0); P=0.02). Strikingly, a patient with an 18% BMI increase showed a dramatic increase of L. reuteri but no increase of E. coli.

Conclusion: The acquired obesity observed in patients treated with vancomycin may be related to a modulation of the gut microbiota rather than a direct antibiotic effect. L. reuteri, which is resistant to vancomycin and produces broad bacteriocins, may have an instrumental role in this effect.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Study flowchart.

Figure 2

Figure 2

Global modification of the gut microbiota during long-term amoxicillin or vancomycin treatment. *P<0.05, **P<0.005, ***P<0.0005 compared with controls. All the significant comparisons have been confirmed after Dunn's multiple comparisons test.

Figure 3

Figure 3

Weight change at 1 year in patients under vancomycin treatment according to the presence or absence of E. coli in the initial gut microbiota. *P<0.05.

Similar articles

Cited by

References

    1. Stokstad EL, Jukes TH. The multiple nature of the animal protein factor. J Biol Chem. 1949;180:647–654. - PubMed
    1. Summary report on antimicrobials sold or distributed for use in food-producing animals. Food and drug administration,2009
    1. Antibiotic resistance back in the news. Animal Health Institute (USA). AHI quaterly1998191–4.
    1. Haight TH, Pierce WE. Effect of prolonged antibiotic administration of the weight of healthy young males. J Nutr. 1955;56:151–161. - PubMed
    1. Ozawa E. Studies on growth promotion by antibiotics. II. Results of aurofac administration to infants. J Antibiot. 1955;8:212–214. - PubMed

LinkOut - more resources